All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
Obesity and type 2 diabetes are diseases of insufficient or deficient regulation. We know from human studies that the small intestine plays a critical role in both energy and glucose homeostasis: when the duodenum is exposed to lipids, appetite is diminished and native (liver) glucose production is down-regulated. Previously we have invented a device that can be implanted into the duodenum and remain in place; we have described devices and methods for slowing the passage of food through the duodenum to cause increased tissue-nutrient contact, thereby causing amplified hormonal signaling from the duodenum; and, we have invented methods and devices for delivering chemicals, drugs or other compounds to the duodenum.
What is needed are devices and/or methods for additional lipid uptake, delaying ingesta passage/prolonging ingesta contact, delivering or providing lipids or other appetite and glucose reducing nutrients and/or combinations of these characteristics.
In one aspect of the present invention, there is provided a device adapted and configured for use within the duodenum of a mammal. The device has a spine having a proximal end and a distal end; an atraumatic feature positioned on at least one of the proximal end and the distal end of the spine; and, positioned along the spine, a flow reduction element having variable porosity along its length. In one embodiment, the variable porosity of the flow reduction element is selected so that a portion of a flow over the proximal end of the flow reduction element flows into an interior portion of the flow reduction element. In one embodiment, the variable porosity of the flow reduction element is selected so that flow within an interior of the flow reduction element is at least partially inhibited from flowing through the distal portion of the variable porosity structure. In one embodiment, the proximal portion of the flow reduction element comprises a material, a mesh or a braid having a porosity or altered to provide a porosity selected to permit a flow into an interior portion of the flow reduction element. In one embodiment, the distal portion of the flow reduction element comprises a material, a mesh or a braid having a porosity or altered to provide a porosity selected to at least partially inhibit a flow from within an interior portion of the flow reduction element. In one embodiment, the length of the spine is selected so when the atraumatic feature is positioned in a stomach the flow reduction element is positioned on the spine and distal to a pylorus. In one embodiment, the length of the spine is selected so when the atraumatic feature is positioned in a stomach the distal end of the spine is in the fourth portion of the duodenum and the flow reduction element is positioned within a portion of the duodenum. In one embodiment, there is also a flow reduction element having a non-variable porosity along its length. In one embodiment, there is also a feature on the spine positioned to restrict movement of the flow reduction element relative to the spine.
In still another aspect of the present invention, there is provided a device adapted and configured for use within the duodenum of a mammal. The device has a spine with a length, a proximal end and a distal end; a first atraumatic feature positioned adjacent to the spine proximal end; a second atraumatic feature positioned adjacent to the spine distal end wherein the length of the spine is selected so that when the first atraumatic feature is in the stomach the second atraumatic feature is in the fourth portion of the duodenum; and a flow reduction element having a proximal end, a distal end, an interior portion, an exterior portion and a variable porosity between the proximal end and the distal end. In one embodiment, the porosity of the proximal end is selected to the allow flow to pass from the exterior portion to the interior portion. In one embodiment, the porosity of the distal end is selected to impede flow from the interior portion to the exterior portion. In one embodiment, the proximal portion is more porous than the distal portion. In one embodiment, the proximal end has a porous structure configured to permit flow into the interior portion and the distal end has a solid portion to retain material within the interior portion. In one embodiment, there is provided another flow reduction element between the proximal and distal ends of the spine. In one embodiment, the another flow reduction element has variable porosity between the proximal and distal ends of the flow reduction element. In one embodiment, the length of the spine is selected so that when the first atraumatic feature is positioned in a stomach the second atraumatic feature is positioned within the duodenum and adjacent to the first atraumatic feature. In one embodiment, the length of the spine is selected so that when the first atraumatic feature is positioned in a stomach the second atraumatic feature is positioned within the duodenum and in proximity to the ligament of Treitz.
In still another aspect, there is provided a method for adjusting the passage of ingesta through the duodenum of a mammal by placing the distal end of a flow reduction device in the duodenum of a mammal; placing the proximal end of the flow reduction device in a stomach of the mammal; expanding within the duodenum of the mammal a variable porosity flow reduction element supported by the flow reduction device; and directing at least a portion of the flow of ingesta through the duodenum through the proximal end of the variable porosity flow reduction element and into an interior portion of the variable porosity flow reduction element. In one embodiment, there is also provided a method retaining a portion of the ingesta within the interior portion of the variable porosity flow reduction element until the ingesta is pushed out of the interior portion by peristaltic action of the duodenum. In still another embodiment, there is provided a method of adjusting the passage of ingesta wherein the ingesta is pushed out of the interior portion by passing through a distal portion of the variable porosity flow reduction element. In still another alternative method for adjusting the passage of ingesta, the ingesta is pushed out of the interior portion by passing through the proximal portion and thereafter passing around the variable porosity flow reduction element.
In another aspect, the flow reduction elements positioned along the device backbone could be coated with, manufactured from or contain lipid-philic materials. For example, one or more of the flow reduction elements of the intraduodenal device could be manufactured from a lipid absorbing or adsorbing material. A flow reduction element manufactured in this way will attract and collect lipids from passing ingesta and hold the lipids for a period of time. The length of time that the lipids will remain attached to the flow reduction element will vary based on a number of factors. For example, the flow reduction element may exude the lipids as peristalsis continues to squeeze the device. The prolonged presence of and/or sustained release of lipids within the duodenum is believed to benefit and in some cases to increase hormonal regulation. It is to be appreciated that embodiments of the present invention provide prolonged presence of and/or sustained release of lipids within the duodenum through the use of one or more of: making flow reduction elements and/or other components of the flow reduction device (i.e., any of the components of
The present application relates to methods and devices for providing a sense of fullness/satiety and/or glucose production inhibition. The devices and methods described herein provide for additional lipid presence in the duodenum by delaying ingesta passage/prolonging ingesta contact, delivering or providing lipids or other satiety and/or glucose reducing nutrients and/or combinations thereof.
Lipids can be generally defined as substances such as a fat, oil or wax that dissolve in alcohol but not in water. Lipids contain carbon, hydrogen and oxygen but have far less oxygen proportionally than carbohydrates. They serve as a source of fuel and are an important constituent of the structure of cells. As used herein, lipids refer to any of fatty acids, glycerides, complex lipids and nonglycerides. Fatty acids include both saturated and unsaturated. Glycerides include, for example, neutral phosphoglycerides. Complex lipids are lipids complexed with another type of chemical compound and include, for example, lipoproteins, phospholipids and glycolipids. Nonglycerides include, for example, sphingolipds, steroids and waxes.
Because most ingesta contain lipids, it is believed that the methods and devices described herein for prolonging lipid residence time, delaying lipid passage and/or providing lipids would enhance the operating characteristics of a duodenal positioned flow reduction device, such as those described in the related applications. In other words, the methods and devices described herein not only slow the passage of food but may also detain or delay the passage of food. The delay or detention may allow for prolonged nutrient release and aid in achieving health objectives. Additionally or alternatively, the devices and methods described herein may also provide for active introduction of lipids into the duodenum.
Catch and hold food, some of which is lipid. By using flow reduction bulges along the spine of the device pictured in
The flow restriction devices may be any of a wide variety of shapes and dimensions as described in the incorporated patent applications. The adjustment of the flow characteristics of ingesta or chyme: (a) around the outside of a flow reduction element, (b) through a wall of a flow or portion of a flow reduction element and (c) retained within a flow reduction element may be accomplished in a number of ways. One way to adjust the flow characteristics within a flow regulated duodenum (i.e., a duodenum having a flow reduction device implanted within it) is through the porosity or flow characteristics of the flow reduction elements.
As shown in
The flow characteristics of the flow reduction element may be adjusted in a number of ways.
The flow reduction element adjustment may also be accomplished by adjusting the relative amounts of the flow reduction element used for allowing flow (more porous 140) or preventing flow (less porous 150).
The foregoing are merely examples. More than one flow allowing or more than one flow preventing zone or portion may be used in a flow reduction element. While the relative distribution of the flow zones has been generally perpendicular to the spine or flow within the duodenum, other orientations relative to the spine or the duodenum are possible depending upon the desired flow profile. Moreover, a device may have flow reduction elements having one or more flow adjustment zones, or no flow adjustment zones. The type of flow reduction elements and the flow characteristics of those flow reduction elements may be mixed within a flow reduction device depending upon the desired flow characteristics desired.
Other flow reduction element properties such as the shape and size of a reduction element, the relative size between reduction elements, the alignment or orientation of a reduction element to the central shaft or spine and other properties are further described in the incorporated applications and may also be adjusted to accomplish the nutrient delivery aspects described herein.
Alternatively, the flow reduction elements could also be configured to capture and hold a lipid For instance, to maintain a certain lipid level in the spheres, the patient could periodically swallow a lipid ‘pill’ or other form that engages the device and remains in place. The nutrient could also take the form of an extended release compound that releases an amount of the nutrient over time. The nutrient could also be mixed with another compound that is released when the patient consumes a releasing agent, such as before a meal or at a time of day prone to hunger pangs or higher than desired blood glucose levels. The releasing agent mixes with the nutrient compound mixture causing the release of nutrients, such as lipids, to aid in regulation of hunger and/or glucose.
In another aspect, the flow reduction device could be coated with, manufactured with or contain nutrients such as lipids or lipid-philic materials. For example, the flow reduction elements could be one or more bulges manufactured using lipid leaching materials; or the bulges could be manufactured with lipid-philic materials or a sponge like membrane inside the bulges or otherwise connected to the device backbone, that would absorb and distribute temporally lipids from passing ingesta to increase hormonal regulation.
In another aspect, the flow reduction elements positioned along the device backbone could be coated with, manufactured from or contain lipid-philic materials. For example, one or more of the flow reduction elements of the intraduodenal device could be manufactured from a lipid absorbing or adsorbing material. A flow reduction element manufactured in this way will attract and collect lipids from passing ingesta and hold the lipids for a period of time. The length of time that the lipids will remain attached to the flow reduction element will vary based on a number of factors. For example, the flow reduction element may exude the lipids as peristalsis continues to squeeze the device. The prolonged presence of and/or sustained release of lipids within the duodenum is believed to benefit and in some cases to increase hormonal regulation. It is to be appreciated that embodiments of the present invention provide prolonged presence of and/or sustained release of lipids within the duodenum through the use of one or more of: making flow reduction elements and/or other components of the flow reduction device (i.e., any of the components of
The spine could be configured as a central tube with plural inlet/outlet ports in communication with a flow reduction element and/or the outside of the tube as described in the incorporated applications. Additionally or alternatively, a portion of the device itself, i.e.: the backbone or spine, could be hollow such that it could be filled with lipids that would leach out or otherwise be delivered to the duodenum. A nutrient reservoir may be implanted within the patient, within the flow reduction device or separately injected into the device during implantation, after insertion or periodically while the patient has the device inserted in his duodenum.
Additionally or alternatively, the lipid equipped hormonal regulatory device could be configured to release lipids on demand using an internal or external controller or device as described in U.S. patent application Ser. No. 11/807,107, filed May 25, 2007, entitled “METHODS AND DEVICES TO CURB APPETITE AND/OR REDUCE FOOD INTAKE,” now Publication No. 2007-0293885.
This application is a continuation of U.S. patent application Ser. No. 12/999,180, filed Jan. 31, 2011, entitled “METHODS AND DEVICES FOR DELIVERING OR DELAYING LIPIDS WITHIN A DUODENUM,” now Publication No. 2011-0137227, which is a 35 U.S.C. §371 national phase application of International Patent Application No. PCT/US2009/049586, filed Jul. 2, 2009, entitled “METHODS AND DEVICES FOR DELIVERING OR DELAYING LIPIDS WITHIN A DUODENUM,” now Publication No. WO 2010/003097, which claims the benefit of priority of U.S. Provisional Patent Application No. 61/077,579, filed Jul. 2, 2008, entitled “METHODS AND DEVICES FOR DELIVERING OR DELAYING LIPIDS WITHIN A DUODENUM” and is also a continuation-in-part of International Patent Application No. PCT/US2008/070226, filed Jul. 16, 2008, entitled “CONFORMATIONALLY-STABILIZED INTRALUMINAL DEVICE FOR MEDICAL APPLICATIONS,” now Publication No. WO 2009/012335 A1, the entirety of each of these applications is incorporated herein by reference in its entirety. Various aspects of the design, function, deployment, operation and delivery of conformal flow reduction devices for use in the duodenum are described in the following related applications: U.S. Provisional Patent Application No. 60/950,071, filed Jul. 16, 2007, entitled “CONFORMATIONALLY-STABILIZED INTRALUMINAL DEVICE FOR MEDICAL APPLICATIONS,” now International Patent Application No. PCT/US2008/070226, filed Jul. 16, 2008, entitled “A CONFORMATIONALLY-STABILIZED INTRALUMINAL DEVICE FOR MEDICAL APPLICATIONS,” now Publication No. WO 2009/012335; U.S. patent application Ser. No. 10/999,410, filed Nov. 30, 2004, entitled “METHOD AND APPARATUS FOR REDUCING OBESITY,” now U.S. Pat. No. 7,931,693; U.S. patent application Ser. No. 11/300,283, filed Dec. 15, 2005, entitled “METHODS AND DEVICES TO CURB APPETITE AND/OR REDUCE FOOD INTAKE,” now U.S. Pat. No. 8,147,561; and U.S. patent application Ser. No. 11/807,107, filed May 25, 2007, entitled “METHODS AND DEVICES TO CURB APPETITE AND/OR REDUCE FOOD INTAKE,” now Publication No. 2007-0293885.
Number | Name | Date | Kind |
---|---|---|---|
2773502 | Kaslow et al. | Dec 1956 | A |
3546961 | Marton | Dec 1970 | A |
4133315 | Berman et al. | Jan 1979 | A |
4134405 | Smit | Jan 1979 | A |
4315509 | Smit | Feb 1982 | A |
4416267 | Garren et al. | Nov 1983 | A |
4485805 | Foster, Jr. | Dec 1984 | A |
4501264 | Rockey | Feb 1985 | A |
4648383 | Angelchik | Mar 1987 | A |
4694827 | Weiner et al. | Sep 1987 | A |
4878905 | Blass | Nov 1989 | A |
4899747 | Garren et al. | Feb 1990 | A |
5019400 | Gombotz et al. | May 1991 | A |
5084061 | Gau et al. | Jan 1992 | A |
5234454 | Bangs | Aug 1993 | A |
5259399 | Brown | Nov 1993 | A |
5329942 | Gunther et al. | Jul 1994 | A |
5396880 | Kagan et al. | Mar 1995 | A |
5439476 | Frantzides | Aug 1995 | A |
5484610 | Bae | Jan 1996 | A |
5597797 | Clark | Jan 1997 | A |
5820584 | Crabb | Oct 1998 | A |
5868141 | Ellias | Feb 1999 | A |
6102922 | Jakobsson et al. | Aug 2000 | A |
6160084 | Langer et al. | Dec 2000 | A |
6187330 | Wang et al. | Feb 2001 | B1 |
6264700 | Kilcoyne et al. | Jul 2001 | B1 |
6267988 | Meyer | Jul 2001 | B1 |
6281262 | Shikinami | Aug 2001 | B1 |
6302917 | Dua et al. | Oct 2001 | B1 |
6306163 | Fitz | Oct 2001 | B1 |
6336934 | Gilson et al. | Jan 2002 | B1 |
6365173 | Domb et al. | Apr 2002 | B1 |
6388043 | Langer et al. | May 2002 | B1 |
6402687 | Ouchi | Jun 2002 | B1 |
6540789 | Silverman et al. | Apr 2003 | B1 |
6579301 | Bales et al. | Jun 2003 | B1 |
6635431 | Bihain et al. | Oct 2003 | B1 |
6685957 | Bezemer et al. | Feb 2004 | B1 |
6716444 | Castro et al. | Apr 2004 | B1 |
6720402 | Langer et al. | Apr 2004 | B2 |
6740121 | Geitz | May 2004 | B2 |
6800056 | Tartaglia et al. | Oct 2004 | B2 |
6939557 | Rowe et al. | Sep 2005 | B2 |
6946002 | Geitz | Sep 2005 | B2 |
6953560 | Castro et al. | Oct 2005 | B1 |
7025791 | Levine et al. | Apr 2006 | B2 |
7037344 | Kagan et al. | May 2006 | B2 |
7111627 | Stack et al. | Sep 2006 | B2 |
7121283 | Stack et al. | Oct 2006 | B2 |
7122058 | Levine et al. | Oct 2006 | B2 |
7175669 | Geitz | Feb 2007 | B2 |
7223277 | DeLegge | May 2007 | B2 |
7335210 | Smit | Feb 2008 | B2 |
7931693 | Binmoeller | Apr 2011 | B2 |
8147561 | Binmoeller | Apr 2012 | B2 |
20020002384 | Gilson et al. | Jan 2002 | A1 |
20020035347 | Bagaoisan et al. | Mar 2002 | A1 |
20020035361 | Houser et al. | Mar 2002 | A1 |
20020111648 | Kusleika et al. | Aug 2002 | A1 |
20030040804 | Stack et al. | Feb 2003 | A1 |
20030199990 | Stack et al. | Oct 2003 | A1 |
20040015187 | Lendlein et al. | Jan 2004 | A1 |
20040030347 | Gannoe et al. | Feb 2004 | A1 |
20040044353 | Gannoe | Mar 2004 | A1 |
20040044354 | Gannoe et al. | Mar 2004 | A1 |
20040088022 | Chen | May 2004 | A1 |
20040092892 | Kagan et al. | May 2004 | A1 |
20040110285 | Lendlein et al. | Jun 2004 | A1 |
20040122456 | Saadat et al. | Jun 2004 | A1 |
20040153118 | Clubb et al. | Aug 2004 | A1 |
20040219186 | Ayres | Nov 2004 | A1 |
20040267378 | Gazi et al. | Dec 2004 | A1 |
20050004681 | Stack et al. | Jan 2005 | A1 |
20050033331 | Burnett | Feb 2005 | A1 |
20050033332 | Burnett et al. | Feb 2005 | A1 |
20050038415 | Rohr et al. | Feb 2005 | A1 |
20050049718 | Dann et al. | Mar 2005 | A1 |
20050055014 | Coppeta et al. | Mar 2005 | A1 |
20050055039 | Burnett et al. | Mar 2005 | A1 |
20050075405 | Wilson et al. | Apr 2005 | A1 |
20050075622 | Levine et al. | Apr 2005 | A1 |
20050080395 | Levine et al. | Apr 2005 | A1 |
20050080431 | Levine et al. | Apr 2005 | A1 |
20050080491 | Levine et al. | Apr 2005 | A1 |
20050090873 | Imran | Apr 2005 | A1 |
20050119674 | Gingras | Jun 2005 | A1 |
20050125020 | Meade et al. | Jun 2005 | A1 |
20050125075 | Meade et al. | Jun 2005 | A1 |
20050183732 | Edwards | Aug 2005 | A1 |
20050238694 | Gerhardt et al. | Oct 2005 | A1 |
20050245719 | Mather et al. | Nov 2005 | A1 |
20050273060 | Levy et al. | Dec 2005 | A1 |
20050277975 | Saadat et al. | Dec 2005 | A1 |
20060020278 | Burnett et al. | Jan 2006 | A1 |
20060064120 | Levine et al. | Mar 2006 | A1 |
20060079944 | Imran | Apr 2006 | A1 |
20060086362 | Solomon | Apr 2006 | A1 |
20060129237 | Imran | Jun 2006 | A1 |
20060142794 | Lendlein et al. | Jun 2006 | A1 |
20060155311 | Hashiba et al. | Jul 2006 | A1 |
20060161139 | Levine et al. | Jul 2006 | A1 |
20060161172 | Levine et al. | Jul 2006 | A1 |
20060161187 | Levine et al. | Jul 2006 | A1 |
20060161265 | Levine et al. | Jul 2006 | A1 |
20060247718 | Starkebaum | Nov 2006 | A1 |
20060259051 | Nissl | Nov 2006 | A1 |
20060265082 | Meade et al. | Nov 2006 | A1 |
20060282107 | Hashiba et al. | Dec 2006 | A1 |
20070005147 | Levine et al. | Jan 2007 | A1 |
20070010864 | Dann et al. | Jan 2007 | A1 |
20070010865 | Dann et al. | Jan 2007 | A1 |
20070027548 | Levine et al. | Feb 2007 | A1 |
20070083271 | Levine et al. | Apr 2007 | A1 |
20070110793 | Kantrowitz et al. | May 2007 | A1 |
20070135768 | Carlsen | Jun 2007 | A1 |
20070156159 | Gannoe et al. | Jul 2007 | A1 |
20070156248 | Marco et al. | Jul 2007 | A1 |
20070239284 | Skerven et al. | Oct 2007 | A1 |
20070265598 | Karasik | Nov 2007 | A1 |
20070282418 | Weitzner | Dec 2007 | A1 |
20070293885 | Binmoeller et al. | Dec 2007 | A1 |
20080065136 | Young | Mar 2008 | A1 |
20080097510 | Albrecht et al. | Apr 2008 | A1 |
20080234834 | Meade et al. | Sep 2008 | A1 |
20090187206 | Binmoeller et al. | Jul 2009 | A1 |
20110137227 | McKinley et al. | Jun 2011 | A1 |
20110190684 | Binmoeller | Aug 2011 | A1 |
20120172999 | Binmoeller | Jul 2012 | A1 |
20130109912 | Binmoeller et al. | May 2013 | A1 |
20140100513 | Binmoeller | Apr 2014 | A1 |
20140114228 | Binmoeller et al. | Apr 2014 | A1 |
Number | Date | Country |
---|---|---|
4012642 | Oct 1991 | DE |
01015063 | Jan 1989 | JP |
2004509714 | Apr 2004 | JP |
WO 8900407 | Jan 1989 | WO |
WO 03094785 | Nov 2003 | WO |
WO 2004041133 | May 2004 | WO |
WO 2004093753 | Nov 2004 | WO |
WO 2005120363 | Dec 2005 | WO |
WO 2006044640 | Apr 2006 | WO |
WO 2006092789 | Sep 2006 | WO |
WO 2006102240 | Sep 2006 | WO |
WO 2007030829 | Mar 2007 | WO |
WO 2007053556 | May 2007 | WO |
WO 2007053706 | May 2007 | WO |
WO 2007053707 | May 2007 | WO |
WO 2007075396 | Jul 2007 | WO |
WO 2007139920 | Dec 2007 | WO |
WO 2008001381 | Jan 2008 | WO |
WO 2009012335 | Jan 2009 | WO |
Entry |
---|
Burnett, Daniel R.; U.S. Appl. No. 60/490,421 entitled “Pyloric valve corking device and method,” filed Jul. 28, 2003. |
Burnett, Daniel R.; U.S. Appl. No. 60/525,105 entitled “Intragastric therapeutic device and method,” filed Nov. 28, 2003. |
Asakawa et al., “Characterization of the effects of pancreatic polypeptide in the regulation of energy balance,” Gastroenterology 124(5):1325-36 (May 2003). |
Batterham et al., “Gut hormone PYY(3-36) physiologically inhibits food intake,” Nature 418(6898): 650-4 (Aug. 8, 2002). |
Batterham et al., “Inhibition of food intake in obese subjects by peptide YY3-36,” 0N Engl J Med., 349(10):941-8 (Sep. 4, 2003). |
Batterham et al., “Pancreatic polypeptide reduces appetite and food intake in humans,” J Clin Endocrinol Metab. 88(8):3989-92 (Aug. 2003). |
Caro et al., “Leptin: the tale of an obesity gene,” Diabetes 45(11): 1455-62 (Nov. 1996). |
Chapman et al., “Effects of small-intestinal fat and carbohydrate infusions on appetite and food intake in obese and nonobese men,” Am J Clin Nutr, vol. 69, pp. 6-12 (Jan. 1999). |
Cohen et al., “Oxyntomodulin suppresses appetite and reduces food intake in humans,” J Clin Endocrinol Metab., 88(10): 4696-4701 (Oct. 2003). |
Collins et al., “Role of leptin in fat regulation,” Nature, 380 (6576):677 (Apr. 25, 1996). |
D'Alessio et al., “Activation of the parasympathetic nervous system is necessary for normal meal-induced insulin secretion in rhesus macaques,” J Clin Endocrinol Metab., 86(3): 1253-9 (Mar. 2001). |
Davis et al., “Distension of the small intestine, satiety, and the control of food intake,” Am Journal of Clinical Nutrition, vol. 31, pp. S255-S258 (Oct. 1978). |
de Castro et al., “A general model of intake regulation,” Neuroscience and Biobehavioral Reviews, vol. 26(5), pp. 581-595 (Aug. 2002). |
French et al.,“Is Cholecystokinin a Satiety Hormone? Correlations of Plasma Cholecystokinin with Hunger, Satiety, and Gastric Empyting in Normal Volunteers,” Appetite, vol. 16, pp. 95-104 (Oct. 1993). |
Gao et al., “Sensory and biomechanical responses to ramp-controlled distension of the human duodenum,” Am. J. Physiol. Gas., vol. 284, pp. G461-G471 (Mar. 2003). |
Geliebter et al., “Clinical trial of silicone rubber gastric balloon to treat obesity,” Int J Obesity, 15(4): 259-266 (Apr. 1991). |
Ghatei et al., Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract, J Clin Endocrinol Metab, 57(3):488-95 (Sep. 1983). |
Gibbs et al., “Cholecystokinin descreases food intake in rats,” J Comp Physiol Psychol. 84(3):488-95 (Sep. 1973). |
Havel, Peter, “Peripheral signals conveying metabolic information to the brain: Short-term and long-term regulation of food intake and energy homeostasis,” Society for Experimental Biology and Medicine, vol. 226, pp. 963-977 (Dec 2001). |
Havel, PJ, “Role of adipose tissue in body-weight regulation: mechanisms regulating leptin production and energy balance,” Proc Nutr Soc. 59(3):359-71 (Aug. 2000). |
Haynes et al., “Receptor-mediated regional sympathetic nerve activation by leptin,” J Clin Invest. 100(2): 270-278 (Jul. 15, 1997). |
Herrmann et al., “Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients,” Digestion 56(2);117-26; (year of publication is sufficiently earlier than the effective U.S. filing and any foreign priority date ) 1995. |
Kissileff et al., “Peptides that Regulate Food Intake: Cholecystokinin and stomach distension combine to reduce food intake in humans,” Am J Physiol Regul Integr Comp Physiol., 285(5):R992-8 (Nov. 2003). |
Le Quellec et al., “Oxyntomodulin-like immunoreactivity: diurnal profile of a new potential entergastrone,” J Clin Endocrinol Metab, 74(6): 1405-9 (Jun. 1992). |
Levin et al., “Decreased food intake does not completely account for adiposity reduction after ob protein infusion,” Proc Natl Acad Sci U.S.A., 93(4): 1726-30 (Feb. 20, 1996). |
Liddle et al., “Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction,” J Clin Invest. 75(4):1144-52 (Apr. 1985). |
Lindor et al., “Intragastric balloons in comparison with standard therapy for obesity—a randomized, double-blind trial,” Mayo Clin Proc 62(11): 992-6 (Nov. 1987). |
Malaisse-Lagae et al., “Pancreatic polypeptide: a possible role in the regulation of food intake in the mouse. (Hypothesis)” Experientia 15; 33(7):915-917 (Jul. 15, 1977). |
Mathus-Vliegen et al., “Intragastric balloon in the treatment of super-morbid obesity. Double-blind, sham-controlled, crossover evaluation of 500-millimeter balloon,” Gastroenterology, 99(2): 362-369 (Aug. 1990). |
Moran el al, “Neurobiology of cholecystokinin,” Crit Rev Neurobiol. 9(1): 1-28 (year of publication is sufficiently earlier than the effective U.S. filing and any foreign priority date) 1994. |
Moran et al., “Gastrointestinal satiety signals,” Am J Physiol Gastrointest Liver Physiol, vol. 286, pp. G183-G188 (Feb. 1, 2004). |
Näslund et al., “GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans,” Am J Physiol 277 (3 Pt 2):R910-R916 (Sep. 1999). |
Rayner et al., “Effects of cholecystokinin on appetite and pyloric motility during physiological hyperglycermia,” Am J. Physiol. Gastrointest. Liver Physiol. , vol. 278, pp. G98-G104 (Jan. 2000). |
Read et al., “The Role of the Gut in Regulating Food Intake in Man,” Nutrition Reviews, vol. 52, pp. 1-10 (Jan. 1994). |
Read, N.W. “Role of gastrointestinal factors in hunger and satiety in man,” Proceedings of the Nutrition Society, vol. 51, pp. 7-11 (May 1992). |
Remington: The Science and Practice of Pharmacy, 20th Ed., Chap. 47, Controlled Release Drug Delivery Systems. (Jun. 2003). |
Remington's Pharmaceutical Sciences, 17th Ed.; A. R. Gennaro (Editor); “Freeze-drying,” p. 1538-1539 (year of publication is sufficiently earlier than the effective U.S. filing and any foreign priority date) 1985. |
Rigaud et al., “Gastric distension, hunger, and energy intake after balloon implantation in severe obesity,” Int J Obes Relat Metab Disor., 19(7):489-95 (Jul. 1995). |
Ritter, Robert C.; Gastrointestinal mechanisms of satiation for food; Physiol Behav.; 81(2):249-73; Apr. 2004. |
Scarpace et al., “Leptin increases uncoupling protein expression and energy expenditure,” Am J Physiol., 273 (1 Pt 1): E226-230 (Jul. 1997). |
Schirra et al., Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1 (7-36)amide in non-insulin dependent diabetes mellitus, J Endocrinol. 156(1):177-86 (Jan. 1998). |
Schwartz et al., “Central nervous system control of food intake,” Nature, 404(6778): 661-671 (Apr. 6, 2000). |
Schwartz et al., “Keeping hunger at bay,” Nature, vol. 418, pp. 595-597; Aug. 8, 2002. |
Schwartz et al., “Model for the regulation of energy balance and adiposity by the central nervous system,” Am J Clin Nutr., 69(4): 584-96 (Apr. 1999). |
Standring, Susan (ed). Gray's Anatomy, 39th Ed. 1163-64; Nov. 24, 2004. |
Wang et al.; Upper intestinal lipids trigger a gut-brain-liver axis to regulate glucose production; Nature; vol. 452; pp. 1012-1016 (Apr. 24, 2008). |
Wilding, J. P. H., “Neuropeptides and appetite control,” Diabetes U.K. Diabetic Medicine, vol. 19, pp. 619-627 (Aug. 2002). |
Woods et al., “The Regulation of Food Intake by Peptides,” Annals of the New York Academy of Sciences, vol. 575. pp. 236-243; Dec. 1989. |
Wynne et al., “Appetite control,” Journal of Endocrinology, vol. 184, pp. 291-318; Feb. 2005. |
Binmoeller, K.; U.S. Appl. No. 13/768,659 entitled “Methods and devices to curb appetite and/or reduce food intake,” filed Feb. 15, 2013. |
Number | Date | Country | |
---|---|---|---|
20130178782 A1 | Jul 2013 | US |
Number | Date | Country | |
---|---|---|---|
61077579 | Jul 2008 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12999180 | US | |
Child | 13769097 | US |
Number | Date | Country | |
---|---|---|---|
Parent | PCT/US2008/070226 | Jul 2008 | US |
Child | 12999180 | US |